- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07365462
Effekt, sikkerhed og tolerabilitet af NBI-1065890 versus placebo hos voksne med tardiv dyskinesi
En fase 2, randomiseret, dobbeltblind, placebokontrolleret undersøgelse til vurdering af effekt, sikkerhed og tolerabilitet af NBI-1065890 hos voksne deltagere med tardiv dyskinesi
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Neurocrine Medical Information Call Center
- Telefonnummer: 1-877-641-3461
- E-mail: medinfo@neurocrine.com
Studiesteder
-
-
-
Cherven Bryag, Bulgarien, 5980
- Rekruttering
- Neurocrine Clinical Site
-
Plovdiv, Bulgarien, 4004
- Rekruttering
- Neurocrine Clinical Site
-
Sofia, Bulgarien, 1164
- Rekruttering
- Neurocrine Clinical Site
-
Varna, Bulgarien, 9020
- Rekruttering
- Neurocrine Clinical Site
-
-
-
-
Arkansas
-
Bryant, Arkansas, Forenede Stater, 72022
- Rekruttering
- Neurocrine Clinical Site
-
-
California
-
Chino, California, Forenede Stater, 91710
- Rekruttering
- Neurocrine Clinical Site
-
Fountain Valley, California, Forenede Stater, 92708
- Rekruttering
- Neurocrine Clinical Site
-
Huntington Beach, California, Forenede Stater, 92648
- Rekruttering
- Neurocrine Clinical Site
-
Long Beach, California, Forenede Stater, 90807
- Rekruttering
- Neurocrine Clinical Site
-
San Diego, California, Forenede Stater, 92123
- Rekruttering
- Neurocrine Clinical Site
-
Temecula, California, Forenede Stater, 92591
- Rekruttering
- Neurocrine Clinical Site
-
Torrance, California, Forenede Stater, 90501
- Rekruttering
- Neurocrine Clinical Site
-
-
Florida
-
Boca Raton, Florida, Forenede Stater, 33486
- Rekruttering
- Neurocrine Clinical Site
-
Bonita Springs, Florida, Forenede Stater, 34134
- Rekruttering
- Neurocrine Clinical Site
-
Hialeah, Florida, Forenede Stater, 33012
- Rekruttering
- Neurocrine Clinical Site
-
Hialeah, Florida, Forenede Stater, 33013
- Rekruttering
- Neurocrine Clinical Site
-
Miami, Florida, Forenede Stater, 33176
- Rekruttering
- Neurocrine Clinical Site
-
Orange City, Florida, Forenede Stater, 32763
- Rekruttering
- Neurocrine Clinical Site
-
Port Charlotte, Florida, Forenede Stater, 33980
- Rekruttering
- Neurocrine Clinical Site
-
Tampa, Florida, Forenede Stater, 33629
- Rekruttering
- Neurocrine Clinical Site
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30328
- Rekruttering
- Neurocrine Clinical Site
-
Marietta, Georgia, Forenede Stater, 30060
- Rekruttering
- Neurocrine Clinical Site
-
-
Illinois
-
Naperville, Illinois, Forenede Stater, 60563
- Rekruttering
- Neurocrine Clinical Site
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48105
- Rekruttering
- Neurocrine Clinical Site
-
Bloomfield Hills, Michigan, Forenede Stater, 48302
- Rekruttering
- Neurocrine Clinical Site
-
-
Missouri
-
Saint Charles, Missouri, Forenede Stater, 63304
- Rekruttering
- Neurocrine Clinical Site
-
-
Nebraska
-
Lincoln, Nebraska, Forenede Stater, 68526
- Rekruttering
- Neurocrine Clinical Site
-
-
New York
-
Commack, New York, Forenede Stater, 11725
- Rekruttering
- Neurocrine Clinical Site
-
-
Ohio
-
Beachwood, Ohio, Forenede Stater, 44122
- Rekruttering
- Neurocrine Clinical Site
-
Fairlawn, Ohio, Forenede Stater, 44333
- Rekruttering
- Neurocrine Clinical Site
-
-
Texas
-
Austin, Texas, Forenede Stater, 78754
- Rekruttering
- Neurocrine Clinical Site
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- Neurocrine Clinical Site
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Neurocrine Clinical Site
-
Stafford, Texas, Forenede Stater, 77477
- Rekruttering
- Neurocrine Clinical Site
-
-
-
-
-
San Juan, Puerto Rico, 00926
- Rekruttering
- Neurocrine Clinical Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Medically confirmed diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder (MDD) as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) for at least 3 months prior to screening.
- Medically confirmed diagnosis of neuroleptic-induced TD as defined in the DSM-5 for at least 3 months prior to screening.
- Moderate or severe TD (AIMS Item 8, severity of abnormal movement overall) as assessed by a blinded, external AIMS video reviewer using a video recording of the participant's AIMS assessment administered at the clinical site by a blinded, certified site AIMS rater. The AIMS dyskinesia total score (sum of Items 1 to 7) must be ≥6 as assessed by the blinded, external AIMS video reviewer.
Key Exclusion Criteria:
- Comorbid parkinsonism (drug-induced or otherwise) or more than a minimal level of extrapyramidal signs/symptoms, as documented by a score on the Modified Simpson-Angus Scale (mSAS) (excluding Items 8 and 10) >6 at screening or Day -1 (baseline) or a score >3 in any one item (excluding Items 8 and 10).
- Barnes Akathisia Rating Scale (BARS) global clinical assessment score ≥2 at screening or Day -1.
- Brief Psychiatric Rating Scale (BPRS) total score ≥50 at screening or Day -1.
- Hospitalized for schizophrenia, schizoaffective disorder, bipolar disorder, or MDD within 6 months of screening.
- Participant has an unstable medical condition or unstable chronic disease.
- Any known history of neuroleptic malignant syndrome (NMS).
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: NBI-1065890
Participants will receive NBI-1065890. |
Oral administration |
|
Placebo komparator: Placebo
Participants will receive placebo matching NBI-1065890. |
Oral administration |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Ændring fra baseline i den samlede score for dyskinesi på Abnormal Involuntary Movement Scale (AIMS) ved uge 8 baseret på blindede centrale AIMS-videovurdereres vurdering
Tidsramme: Baseline og uge 8
|
Baseline og uge 8
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Procentdel af deltagere, der er en Clinical Global Impression - Improvement (CGI-I) Responder 1 ved uge 8
Tidsramme: Uge 8
|
Uge 8
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Clinical Development Lead, Neurocrine Biosciences
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- NBI-1065890-TD2033
- 2025-524104-30-00 (Ctis)
- 2025 (U.S. NIH-bevilling/kontrakt)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .